Featured Lymphoma Content
Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the clinical treatment options for patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma.
Lymphoma News and Features
The patient's history and current blood work results indicated a dangerously high potassium level. But a meticulously handled redraw proved it false.
Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.
Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.
There is a high incidence of severe acute and persistent cancer-related fatigue in survivors of Hodgkin lymphoma, regardless of tumor stage or treatment.
Lenalidomide is an effective treatment option with limited and reversible toxicities for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), a 'real-world' study has shown.
Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.
Patients living with HIV are at high risk for lymphoma,according to recent study data, and recent autologous hematopoietic stem-cell transplantation may be preferable for these patients.
Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.
Patients with classical Hodgkin lymphoma who are resistant to the CD30-directed antibody-drug conjugate brentuximab vedotin have poor outcomes.
A weekly dose of temsirolimus 75 mg was found to be active in patients with relapsed/refractory primary CNS lymphoma (PCNSL); however, only some patients achieved long-term control.
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
- RANKL Inhibition May Represent Promising Breast Cancer Prevention Strategy
- Bi-allelic Inactivation Common in BRCA1 and BRCA Breast Cancers
- In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS
- High Immune Gene Expression Linked to Better Prognosis in TNBC
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|